Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring

Technology in Cancer Research and Treatment

Volumn 1, Issue 6, 2002, Pages 479-488

  Su, Min Ying ^a   Yu, Hon ^a   Chiou, Jr Yuan ^a   Wang, Jun ^a   Nalcioglu, Orhan ^a   Fruehauf, John P ^b   Mehta, Rita S ^a   Baick, Choong Hyun ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oncotech Inc   (United States)

Author keywords

Breast cancer; Chemotherapy; Contrast Enhanced MRI; Radiation therapy; Therapy response

Indexed keywords

CONTRAST MEDIUM; DOCETAXEL; GADODIAMIDE; GADOMER 17;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; LONGITUDINAL STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; VOLUMETRY;

EID: 0038752640     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460200100608     Document Type: Article

References (27)

1. Gianni, L., Valagussa, P., Zambetti, M., Moliterni, A., Capri, G., Bonadonna, G. Adjuvant and neoadjuvant treatment of breast cancer. Semin. Oncol. 28, 13-29 (2001).
2. Cance, W. G., Carey, L. A., Calvo, B. F., Sartor, C., Sawyer, L., Moore, D. T., Rosenman, J., Ollila, D. W., Graham, M. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: Effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann. Surg. 236, 295-303 (2002).
3. Bonadonna, G., Valagussa, P., Brambilla, C., Ferrari, L., Moliterni, A., Terenziani, M., Zambetti, M. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16, 93-100 (1998).
4. Wolff, A. C., Davidson, N. E. Early operable breast cancer. Curr. Treat. Options. Oncol. 1, 210-220 (2000).
5. Wolff, A. C., Davidson, N. E. Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease. Oncologist 7, 239-245 (2002).
6. Sapunar, F., Smith, I. E. Neoadjuvant chemotherapy for breast cancer. Ann. Med. 32, 43-50 (2000).
7. Stebbing, J. J., Gaya, A. The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer 8, 23-37 (2001).
8. Aapro, M. S. Neoadjuvant therapy in breast cancer: Can we define its role? Oncologist Suppl 3, 36-39 (2001).
9. Smith, I. E., Lipton, L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2, 561-570 (2001).
10. Gilles, R., Guinebretiere, J. M., Toussaint, C., Spielman, M., Rietjens, M., Petit, J. Y., Contesso, G., Masselot, J., Vanel, D. Locally advanced breast cancer: Contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191, 633-638 (1994).
11. Knopp, M. V., Brix, G., Junkermann, H. J., Sinn, H. P. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn. Reson. Imaging Clin. N. Am. 2, 633-658 (1994).
12. Abraham, D. C., Jones, R. C., Jones, S. E., Cheek, J. H., Peters, G. N., Knox, S. M., Grant, M. D., Hampe, D. W., Savino, D. A., Harms, S. E. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78, 91-100 (1996).
13. Trecate, G., Ceglia, E., Stabile, F., Tesoro-Tess, J. D., Mariani, G., Zambetti, M., Musumeci, R. Locally advanced breast cancer treated with primary chemotherapy: Comparison between magnetic resonance imaging and pathologic evaluation of residual disease. Tumori 85, 220-228 (1999).
14. Rieber, A., Brambs, H. J., Gabelmann, A., Heilmann, V., Kreienberg, R., Kuhn, T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 12, 1711-1719 (2002).
15. Tofts, P. S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging. 7, 91-101 (1997).
16. Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B., Lee, T. Y., Mayr, N. A., Parker, G. J., Port, R. E., Taylor, J., Weisskoff, R. M. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J. Magn. Reson. Imaging. 10, 223-232 (1999).
17. Su, M. Y., Wang, Z., Nalcioglu, O. Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. J. Magn. Reson. Imaging. 9, 128-137 (1999).
18. van Dijke, C. F., Brasch, R. C., Roberts, T. P., Weidner, N., Mathur, A., Shames, D. M., Mann, J. S., Demsar, F., Lang, P., Schwickert, H. C. Mammary carcinoma model: Correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 198, 813-818 (1996).
19. Daldrup, H., Shames, D. M., Wendland, M., Okuhata, Y., Link, T. M., Rosenau, W., Lu, Y., Brasch, R. C. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media. AJR Am. J. Roentgenol. 171, 941-949 (1998).
20. Su, M. Y., Jao, J. C., Nalcioglu, O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn. Reson. Med. 32, 714-724 (1994).
21. Su, M. Y., Muhler, A., Lao, X., Nalcioglu, O. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn. Reson. Med. 39, 259-269 (1998).
22. Brasch, R., Turetschek, K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report. Eur. J. Radiol. 34, 148-155 (2000).
23. Esserman, L., Kaplan, E., Partridge, S., Tripathy, D., Rugo, H., Park, J., Hwang, S., Kuerer, H., Sudilovsk, D., Lu, Y., Hylton, N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann. Surg. Oncol. 8, 549-559 (2001).
24. Fletcher, B. D., Hanna, S. L., Fairclough, D. L., Gronemeyer, S. A. Pediatric musculoskeletal tumors: Use of dynamic, contrastenhanced MR imaging to monitor responses to chemotherapy. Radiology 184, 243-248 (1992).
25. Bonnerot, V., Charpentier, A., Frouin, F., Kalifa, C., Vanel, D., Di Paola, R. Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy. Invest. Radiol. 27, 847-855 (1992).
26. Hawighorst, H., Essig, M., Debus, J., Knopp, M. V., EngenhartCabilic, R., Schonberg, S. O., Brix, G., Zuna, I., van Kaick, G. Serial MR imaging of intracranial metastases after radiosurgery. Magn. Reson. Imaging 15, 1121-1132 (1997).
27. Hawighorst, H., Engenhart, R., Knopp, M. V., Brix, G., Grandy, M., Essig, M., Miltner, P., Zuna, I., Fuss, M., van Kaick, G. Intracranial meningeomas: Time- and dose-dependent effects of irradiation on tumor microcirculation monitored by dynamic MR imaging. Magn. Reson. Imaging 15, 423-432 (1997).